We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Read MoreHide Full Article
Key Takeaways
Boston Scientific leverages AI in heart diagnostics, arrhythmia mapping and coronary imaging.
Johnson & Johnson integrates AI in robotic surgery, digital analytics and connected operating rooms.
GE HealthCare and Tempus AI advance AI-powered imaging, precision medicine and clinical decision tools.
Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treatments.
At this stage, it should be fruitful to invest in giant medical stocks focusing rigorously on AI applications. Four such companies are: Boston Scientific Corp. (BSX - Free Report) , Johnson & Johnson (JNJ - Free Report) , GE HealthCare Technologies Inc. (GEHC - Free Report) and Tempus AI Inc. (TEM - Free Report) . Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Increasing AI Applications in Medical Devices
Globally, generative artificial intelligence and agentic AI are increasingly being integrated into medical devices, transforming both clinical workflows and patient care. AI algorithms can analyze patient-specific imaging data or genetic profiles to guide the design of implants, surgical plans, or therapeutic regimens, improving patient outcomes.
Generative AI is primarily being used for content creation and design optimization within the medical device space. Generative AI powers real-time clinical documentation tools embedded within diagnostic devices.
Agentic AI enables medical devices to act autonomously and make decisions based on real-time data. Agentic AI also supports predictive maintenance in connected medical equipment, such as MRIs and ventilators.
Boston Scientific Corp.
Boston Scientific is seeing strength across its target markets despite macroeconomic issues, primarily tariff tensions and related cost inflation. BSX has been investing in AI to support its devices and improve procedural outcomes.
Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally for its next-generation WATCHMAN FLX and FLX Pro are important drivers. BSX’s HeartLogic is a heart failure diagnostic that utilizes AI to detect worsening heart failure in patients with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
The Rhythm AI module in the Rhythmia HDx mapping system can automatically interpret electroanatomical maps to identify arrhythmia circuits, enabling electrophysiologists to target ablation therapy more effectively. BSX’s Coronary Advanced Analysis software uses AI to analyze optical coherence tomography images to characterize plaque.
Boston Scientific has an expected revenue and earnings growth rate of 18.3% and 18.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.4% in the last 30 days.
Image Source: Zacks Investment Research
Johnson & Johnson
Johnson & Johnson boast a major MedTech division (Johnson & Johnson MedTech) focused on medical devices and diagnostics. JNJ applies AI technologies for surgical robotics, digital surgery analytics and imaging. The company has developed an AI-enabled ecosystem called Ottava, its next-gen robotic surgery platform.
JNJ has also developed the Caresurgical/VELYS digital surgery systems, which use data and AI for procedure planning. Its Polyphonic Digital Ecosystem connects operating rooms, allowing surgeons to share live video and data with remote peers. AI in this system helps identify significant events in the surgery video feed for discussion.
Johnson & Johnson has an expected revenue and earnings growth rate of 5.2% and 8.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 30 days.
Image Source: Zacks Investment Research
GE HealthCare Technologies
GE HealthCare Technologies is experiencing strong market demand across the U.S. and global healthcare sectors, driven by rising procedure volumes, hospital capital investments, and increasing adoption of AI-powered imaging and diagnostics. AI is central to GEHC’s digital strategy, which focuses on its precision care framework.
GEHC has launched CleaRecon DL — an AI-driven solution that enhances cone-beam computed tomography image quality. GEHC’s Invenia Automated Breast Ultrasound Premium, the latest 3D ultrasound, offers advanced AI and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts.
GE HealthCare Technologies has an expected revenue and earnings growth rate of 3.5% and 0.9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 12.7% over the last 30 days.
Image Source: Zacks Investment Research
Tempus AI Inc.
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. TEM provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care, and parallel facilitates for the discovery, development and delivery of optimal therapeutics.
TEM’s AI applications include analyzing patient data, generating clinical notes, identifying care gaps, and assisting with treatment decisions, particularly in oncology and cardiology. TEM integrates data including phenotypic, morphologic, and molecular data from different sources to provide a more comprehensive view of a patient's condition.
Tempus AI has an expected revenue and earnings growth rate of 81.1% and 55.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.9% over the last 30 days.
Image Source: Zacks Investment Research
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Key Takeaways
Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treatments.
At this stage, it should be fruitful to invest in giant medical stocks focusing rigorously on AI applications. Four such companies are: Boston Scientific Corp. (BSX - Free Report) , Johnson & Johnson (JNJ - Free Report) , GE HealthCare Technologies Inc. (GEHC - Free Report) and Tempus AI Inc. (TEM - Free Report) . Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Increasing AI Applications in Medical Devices
Globally, generative artificial intelligence and agentic AI are increasingly being integrated into medical devices, transforming both clinical workflows and patient care. AI algorithms can analyze patient-specific imaging data or genetic profiles to guide the design of implants, surgical plans, or therapeutic regimens, improving patient outcomes.
Generative AI is primarily being used for content creation and design optimization within the medical device space. Generative AI powers real-time clinical documentation tools embedded within diagnostic devices.
Agentic AI enables medical devices to act autonomously and make decisions based on real-time data. Agentic AI also supports predictive maintenance in connected medical equipment, such as MRIs and ventilators.
Boston Scientific Corp.
Boston Scientific is seeing strength across its target markets despite macroeconomic issues, primarily tariff tensions and related cost inflation. BSX has been investing in AI to support its devices and improve procedural outcomes.
Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally for its next-generation WATCHMAN FLX and FLX Pro are important drivers. BSX’s HeartLogic is a heart failure diagnostic that utilizes AI to detect worsening heart failure in patients with implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
The Rhythm AI module in the Rhythmia HDx mapping system can automatically interpret electroanatomical maps to identify arrhythmia circuits, enabling electrophysiologists to target ablation therapy more effectively. BSX’s Coronary Advanced Analysis software uses AI to analyze optical coherence tomography images to characterize plaque.
Boston Scientific has an expected revenue and earnings growth rate of 18.3% and 18.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.4% in the last 30 days.
Image Source: Zacks Investment Research
Johnson & Johnson
Johnson & Johnson boast a major MedTech division (Johnson & Johnson MedTech) focused on medical devices and diagnostics. JNJ applies AI technologies for surgical robotics, digital surgery analytics and imaging. The company has developed an AI-enabled ecosystem called Ottava, its next-gen robotic surgery platform.
JNJ has also developed the Caresurgical/VELYS digital surgery systems, which use data and AI for procedure planning. Its Polyphonic Digital Ecosystem connects operating rooms, allowing surgeons to share live video and data with remote peers. AI in this system helps identify significant events in the surgery video feed for discussion.
Johnson & Johnson has an expected revenue and earnings growth rate of 5.2% and 8.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 30 days.
Image Source: Zacks Investment Research
GE HealthCare Technologies
GE HealthCare Technologies is experiencing strong market demand across the U.S. and global healthcare sectors, driven by rising procedure volumes, hospital capital investments, and increasing adoption of AI-powered imaging and diagnostics. AI is central to GEHC’s digital strategy, which focuses on its precision care framework.
GEHC has launched CleaRecon DL — an AI-driven solution that enhances cone-beam computed tomography image quality. GEHC’s Invenia Automated Breast Ultrasound Premium, the latest 3D ultrasound, offers advanced AI and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts.
GE HealthCare Technologies has an expected revenue and earnings growth rate of 3.5% and 0.9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 12.7% over the last 30 days.
Image Source: Zacks Investment Research
Tempus AI Inc.
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. TEM provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care, and parallel facilitates for the discovery, development and delivery of optimal therapeutics.
TEM’s AI applications include analyzing patient data, generating clinical notes, identifying care gaps, and assisting with treatment decisions, particularly in oncology and cardiology. TEM integrates data including phenotypic, morphologic, and molecular data from different sources to provide a more comprehensive view of a patient's condition.
Tempus AI has an expected revenue and earnings growth rate of 81.1% and 55.7%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.9% over the last 30 days.
Image Source: Zacks Investment Research